What is the primary therapeutic benefit of Donepezil in treating Alzheimer's disease?

Donepezil is a cholinesterase inhibitor that primarily works by increasing the levels of acetylcholine, a neurotransmitter that is often deficient in patients with Alzheimer's disease. The primary therapeutic benefit of Donepezil is to improve thinking and functioning abilities in individuals with cognitive decline due to Alzheimer's. By enhancing communication between neurons, Donepezil can help improve memory, awareness, and the ability to perform daily activities, which are critical in managing the symptoms of Alzheimer's disease.

This option focuses on cognitive enhancement rather than directly alleviating other symptoms like hallucinations or depression, which are not the primary targets of Donepezil. While some patients may experience reductions in non-cognitive symptoms as a secondary effect of overall cognitive improvement, the main therapeutic goal of Donepezil is to address deficits in thinking and functioning abilities.